Raymond James Financial
TVTX icon

Raymond James Financial’s Travere Therapeutics TVTX Stock Holding History

Raymond James Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,260
Closed -$33.4K – 6659
2025
Q2 		$33.4K Buy
+2,260
New +$37.5K ﹤0.01% 5352

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Raymond James Financial's TVTX Position: Q3 2025 in Review

Raymond James Financial sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 2,260 shares — an estimated $33.4K sold.

Raymond James Financial first reported a position in TVTX in Q2 2025 and held it in 1 quarter. The position peaked at $33.4K in Q2 2025. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Raymond James Financial reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,260 Travere Therapeutics shares in Q3 2025, an estimated $33.4K.
  • Raymond James Financial first reported a position in Travere Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Travere Therapeutics position peaked at $33.4K in Q2 2025.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.